Macrophage-drug conjugate platform shows preclinical benefits for solid tumor therapy
Feb. 18, 2025
Solid tumors are difficult to treat due to their heterogeneity and limited blood supply, which restrict the effective delivery of anticancer drugs. Macrophages are abundant in solid tumor tissues and are the only cell type actively infiltrating hypoxic tumor regions, making them a promising option for delivering therapeutic agents directly to tumors.